December 2018: AMaRC now has 6 early-phase clinical trials open to recruitment. These studies will evaluate new medications and combinations of therapeutics to enable early access for myeloma patients to emerging therapeutics and improved outcomes.
November 2018: AMaRC representatives were delighted to attend the Australasian Leukaemia and Lymphoma Group (ALLG) Scientific Meeting 2018 in Brisbane. Associate Professor Zoe McQuilten presented on the design of the new FRAIL-M Study, recently funded by the Medical Research Future Fund and to be conducted using the infrastructure of the Myeloma and Related Diseases Registry.
October 2018: AMaRC activities were profiled at the annual investigator meeting of the Myeloma and Related Diseases Registry, held during the BLOOD 2018 conference in Brisbane.
April 2018: The AMaRC Research Advisory Group has been established to provide oversight and guidance on AMaRC research strategy and operations. It includes expert clinician researchers, from around Australia and New Zealand, chaired by Professor Andrew Spencer.
